Figure 5.
Metabolomics Analysis of Aspirin-Derived Metabolites
The 6-week old C57BL/6 mice were injected with unlabeled aspirin (Asp) or [13C]-labeled aspirin (13CAsp) (100 mg/kg, i.p.), followed by mass spectrometry.
(A and D) Volcano plots relative to metabolites detected in the heart (A) and in the liver (D) after unlabeled aspirin injection. Log2FC of Asp/Co-downregulated (green) or -upregulated (blue) metabolites with p value < 0.05 is represented.
(B and E) Volcano plots relative to metabolites detected in the heart (B) and in the liver (E) after [13C]-labeled aspirin injection. Log2FC of 13CAsp/Asp-downregulated (green) or -upregulated (red) metabolites with p value < 0.05 is depicted.
(C and F) Comparison between 13CAsp/Asp (red) and Asp/Co (blue). Log2FC significantly changed (p value < 0.05) in the heart (C) and in the liver (F) is graphed. The blue box highlights salicylate, which represents a commonly upregulated metabolite in all organs assessed.
(G and H) Heatmap (Log2FC) of 13CAsp/Asp metabolites in different organs (G) is shown. [13C]-Aspirin administration allows the identification of bona fide aspirin-derived metabolites, which are distributed in an organ-specific fashion. Common upregulated metabolites are highlighted with a blue box. Magnification is shown in (H). Pre-annotated metabolites are as follows: SA[∗]@4.14, salicylic acid, positive mode; GenA[∗]@4.07(-), gentisic/2-pyrocatechuic acid; SA[∗]@5.00(-), salicylic acid, negative mode; SuA[∗]@4.57(-), salicyluric acid; and SaGlc[∗]@3.76(-), salicylate glucuronide. Details are available in Table S2.